Acrin And Tomosynthesis Restate Thesis Statement In Conclusion

As many as 10% of women who have a routine screening mammogram will be asked to have additional mammographic views and possibly an ultrasound.The majority of these women - up to 80 percent - will experience what’s called a “false-positive” which means that an area that looked suspicious on their screening mammogram turned out, upon further testing, to be normal.The TMIST trial is for healthy women ages 45 to 74 who are already planning to get a routine mammogram.The participants will provide critical information that will inform the study, which seeks to change breast cancer screening to a more personalized approach.Pisano, MD, professor in residence at Beth Israel Deaconess Medical Center and Harvard Medical School, and chief science officer at the Center for Research and Innovation at the American College of Radiology.

Acrin And Tomosynthesis-67Acrin And Tomosynthesis-40

“TMIST will provide solid evidence as to the impact that we can expect in reducing the burden of breast cancer on women and their loved ones.” More than 3000 Canadian women participated in a lead-in study led by Dr.The large scale North American study was developed by the US based ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), with the Canadian Cancer Trials Group (CCTG) coordinating the trial in Canada (more national sites will be opening the trial over the next several months).“There is no science to show that seeing more makes 3-D any better than 2-D at finding more of the aggressive types of breast cancer early,” said ECOG-ACRIN study chair Etta D.Although patients will notice little difference between 2D and 3D mammograms, the 3D technology gives the radiologist a clearer view through the overlapping structures of breast tissue.Reading a breast tomosynthesis exam is like flipping through the pages of a book to view one page at a time instead of seeing the whole breast reduced to a single frame, as is the case with conventional 2D mammography.Dynamic multiplanar reconstructions allow the user to adjust reconstruction and display parameters interactively, including axial sampling, slice location, plane tilt…The Sunnybrook Health Sciences Centre and the Ottawa Hospital are currently enrolling women in the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare conventional mammography (2-D) to the newer digital tomosynthesis method (3-D).It is not known if this newer mammography technology is reducing a woman’s risk of developing a life-threatening (advanced) cancer compared with 2-D mammography.At participating centers, women (45 to 75) will be told about the trial when they schedule their routine mammogram and once enrolled are then randomly assigned to either 2-D or 3-D mammography screening for the next five years.About the MAC.22 (TMIST) trial The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), is the first randomized trial to compare two types of digital mammography for breast cancer screening: tomosynthesis (known as three-dimensional, or 3-D) and conventional (two-dimensional, or 2-D).Although 3-D mammography, is a newer technology it will likely detect more findings that require follow-up, it is also likely to lead to more procedures and treatments.

Leave a Reply

Your email address will not be published. Required fields are marked *

One thought on “Acrin And Tomosynthesis”